A Phase I/II Multi-Center, Randomized, Double-Masked, Placebo-Controlled, Dose-Escalation Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Pharmacodynamics (Efficacy) of Chronic Twice-Daily Topical Monocular Application of INO-8875 Ophthalmic Formulation in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma

Trial Profile

A Phase I/II Multi-Center, Randomized, Double-Masked, Placebo-Controlled, Dose-Escalation Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Pharmacodynamics (Efficacy) of Chronic Twice-Daily Topical Monocular Application of INO-8875 Ophthalmic Formulation in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma

Completed
Phase of Trial: Phase I/II

Latest Information Update: 11 Apr 2016

At a glance

  • Drugs Trabodenoson (Primary)
  • Indications Ocular hypertension; Open-angle glaucoma
  • Focus Adverse reactions
  • Sponsors Inotek Pharmaceuticals
  • Most Recent Events

    • 11 Apr 2016 According to an Inotek Pharmaceuticals media release, results from this trial were published in the Journal of Ocular Pharmacology and Therapeutics.
    • 11 Apr 2016 Results published in the Inotek Pharmaceuticals media release.
    • 08 Oct 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top